Ziarco, a UK biopharmaceutical company focusing on inflammatory and allergic diseases, has appointed David Brinkley to the Board of Directors to provide input on the company’s corporate, R&D strategy and business plans.
Brinkley was recently Head of Business Development at Theravance and had previously served as Senior Vice President, Commercial Development at the firm from September 2000 to December 2007, when he left to start a consulting practice.
From 1996 to 2000 Brinkley was Worldwide Team Leader for Viagra at Pfizer. He joined Pfizer in 1995 through its acquisition of SmithKline Beecham's Animal Health operations and was Director of new product planning before leading the Viagra launch team. Brinkley also held various management positions with SmithKline from 1983 to 1995.
Ziarco is based in Canterbury, Kent. It was set up last year by Mike Yeadon formerly Chief Scientist in the allergy and respiratory research unit of Pfizer in Sandwich, Kent.
